Nervous regulation: beta-2-adrenergic signaling in immune homeostasis, cancer immunotherapy, and autoimmune diseases Sagarina ThapaXuefang Cao Review 15 April 2023 Pages: 2549 - 2556
BAP1-related signature predicts benefits from immunotherapy over VEGFR/mTOR inhibitors in ccRCC: a retrospective analysis of JAVELIN Renal 101 and checkmate-009/010/025 trials Kan LiuYan HuangTaoping Shi Research 12 April 2023 Pages: 2557 - 2572
Cytotoxicity of CD19-CAR-NK92 cells is primarily mediated via perforin/granzyme pathway Jonas AlthausVerena Nilius-EliliwiThomas Mika Research Open access 13 April 2023 Pages: 2573 - 2583
Characteristic differences in the abundance of tumor-infiltrating lymphocytes and intratumoral developing T cells in thymoma, with special reference to PD-1 expression Tatsuo FuruyaShunta IshiharaMasayoshi Inoue Research 15 April 2023 Pages: 2585 - 2596
Engineered murine IL-21-secreting leukemia cells induce granzyme B+ T cells and CD4+CD44+CD62L− effector memory cells while suppressing regulatory T cells, leading to long-term survival Alexandra BergerSarah J. ColpittsChristopher J. Paige Research 15 April 2023 Pages: 2597 - 2612
Incidence of serious adverse events caused by tyrosine kinase inhibitor treatment following immune checkpoint inhibitor therapy in advanced NSCLC patients with oncogenic driver alterations Yukiko ShimodaTatsuya YoshidaYuichiro Ohe Research 16 April 2023 Pages: 2613 - 2621
Switchable CAR T cell strategy against osteosarcoma Laura HidalgoBeatriz Somovilla-CrespoJavier Garcia-Castro Research Open access 16 April 2023 Pages: 2623 - 2633
The pathogenetic significance of exhausted T cells in a mouse model of mature B cell neoplasms Asuka ShibamiyaYurie Miyamoto-NagaiNaoya Mimura Research 17 April 2023 Pages: 2635 - 2648
Safety and efficacy of the anti-PD1 immunotherapy with nivolumab in trichoblastic carcinomas E. ToulemondeS. ChevretL. Mortier Research 17 April 2023 Pages: 2649 - 2657
Characterizing the tumor immune microenvironment of ependymomas using targeted gene expression profiles and RNA sequencing W. de KoningF. F. FeenstraD. A. M. Mustafa Research Open access 19 April 2023 Pages: 2659 - 2670
Massively recruited sTLR9+ neutrophils in rapidly formed nodules at the site of tumor cell inoculation and their contribution to a pro-tumor microenvironment Mengyuan KouWenting LuYongli Yu Research 20 April 2023 Pages: 2671 - 2686
Phenotypic and functional analysis in HER2+ targeted therapy of human NK cell subpopulation according to the expression of FcεRIγ and NKG2C in breast cancer patients María B. BordignonAyelén I. Pesce VigliettiEstrella M. Levy Research 21 April 2023 Pages: 2687 - 2700
Identification of a novel immune checkpoint molecule V-set immunoglobulin domain-containing 4 that leads to impaired immunity infiltration in pancreatic ductal adenocarcinoma Yongsheng JiangLijie HanHao Chen Research Open access 25 April 2023 Pages: 2701 - 2716
Cytokine profiling identifies circulating IL-6 and IL-15 as prognostic stratifiers in patients with non-small cell lung cancer receiving anti-PD-1/PD-L1 blockade therapy Yusuke InoueNaoki InuiTakafumi Suda Research 26 April 2023 Pages: 2717 - 2728
Phase I study of MSB2311, a novel pH-dependent anti-PD-L1 monoclonal antibody, treating patients with advanced solid tumors and lymphoma Qi ZhangJian ZhangXichun Hu Research 28 April 2023 Pages: 2729 - 2739
Self-assembled nanoparticles based on DNA origami and a nitrated T helper cell epitope as a platform for the development of personalized cancer vaccines Yanliang KangWanli ZhangWenbing Yao Research 29 April 2023 Pages: 2741 - 2755
Improved predictability of pancreatic ductal adenocarcinoma diagnosis using a blood immune cell biomarker panel developed from bulk mRNA sequencing and single-cell RNA-sequencing Sung Ill JangHyung Keun LeeDong Ki Lee Research Open access 10 May 2023 Pages: 2757 - 2768
Single-center phase 2 study of PD-1 inhibitor combined with DNA hypomethylation agent + CAG regimen in patients with relapsed/refractory acute myeloid leukemia Xiao-Ning GaoYong-Feng SuDai-Hong Liu Research 11 May 2023 Pages: 2769 - 2782
Exploiting docetaxel-induced tumor cell necrosis with tumor targeted delivery of IL-12 S. Elizabeth FranksGinette S. Santiago-SanchezJames W. Hodge Research Open access 11 May 2023 Pages: 2783 - 2797
Brachyury-targeted immunotherapy combined with gemcitabine against head and neck cancer Hidekiyo YamakiMichihisa KonoAkihiro Katada Research 12 May 2023 Pages: 2799 - 2812
Induction of cancer neoantigens facilitates development of clinically relevant models for the study of pancreatic cancer immunobiology Usman Y. PanniMichael Y. ChenWilliam G. Hawkins Research Open access 13 May 2023 Pages: 2813 - 2827
Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitors Hidetomo HimuroYoshiro NakaharaTetsuro Sasada Research 16 May 2023 Pages: 2829 - 2840
Sequential CAR T cell and targeted alpha immunotherapy in disseminated multiple myeloma Dennis AwuahMegan MinnixXiuli Wang Research Open access 20 May 2023 Pages: 2841 - 2849
Enhanced HPV16 E6/E7+ tumor eradication via induction of tumor-specific T cells by therapeutic vaccination with virosomes presenting synthetic long peptides Toon StegmannAnna-Sophia WiekmeijerCornelis J. M. Melief Research Open access 24 May 2023 Pages: 2851 - 2864
Immunoreactivity to WT1 peptide vaccine is associated with prognosis in elderly patients with acute myeloid leukemia: follow-up study of randomized phase II trial of OCV-501, an HLA class II-binding WT1 polypeptide Tomoki NaoeAkiko SaitoHirokazu Nagai Brief Report Open access 24 April 2023 Pages: 2865 - 2871
Correction to: Increased TIGIT expressing NK cells with dysfunctional phenotype in AML patients correlated with poor prognosis Guanfang LiuQi ZhangErxia Shen Correction 08 May 2023 Pages: 2873 - 2873
Correction to: IL‑17A promotes fatty acid uptake through the IL‑17A/IL‑17RA/ p‑STAT3/FABP4 axis to fuel ovarian cancer growth in an adipocyte‑rich microenvironment Chunyan YuXiulong NiuWeimin Deng Correction 15 May 2023 Pages: 2875 - 2877
